PMID- 8579117
OWN - NLM
STAT- MEDLINE
DCOM- 19960311
LR  - 20211203
IS  - 0002-9440 (Print)
IS  - 1525-2191 (Electronic)
IS  - 0002-9440 (Linking)
VI  - 148
IP  - 2
DP  - 1996 Feb
TI  - Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary 
      carcinoma and differentially associated with steroid receptors.
PG  - 549-58
AB  - The neu/erbB-2/HER-2 proto-oncogene is amplified and/or overexpressed in up to 
      30% of mammary carcinomas and has been variably correlated with poor prognosis. 
      The signaling activity of the encoded receptor tyrosine kinase is regulated by 
      interactions with other type 1 receptors and their ligands. We have used a novel 
      approach, phosphorylation-sensitive anti-Neu antibodies, to quantify signaling by 
      Neu and epidermal growth factor receptor in a panel of frozen sections of mammary 
      carcinoma specimens. We also determined the relationship of Neu, phosphorylated 
      Neu (and epidermal growth factor receptor), and phosphotyrosine to the expression 
      of Neu-related receptors (epidermal growth factor receptor, HER-3, and HER-4) and 
      to prognostic factors (estrogen and progesterone receptor). We found that 
      tyrosine phosphorylation of Neu (and hence signaling activity) is highly variable 
      among mammary carcinomas. Neu and HER-4 were associated with divergent 
      correlates, suggesting that they have profoundly different biological activities. 
      These results have implications for etiology of mammary carcinoma for clinical 
      evaluation of mammary carcinoma patients, and for development of Neu-targeted 
      therapeutic strategies.
FAU - Bacus, S S
AU  - Bacus SS
AD  - Advanced Cellular Diagnostics, Inc., Elmhurst, Illinois, USA.
FAU - Chin, D
AU  - Chin D
FAU - Yarden, Y
AU  - Yarden Y
FAU - Zelnick, C R
AU  - Zelnick CR
FAU - Stern, D F
AU  - Stern DF
LA  - eng
GR  - 5-P20-CA58202/CA/NCI NIH HHS/United States
GR  - CA45708/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Am J Pathol
JT  - The American journal of pathology
JID - 0370502
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 0 (Receptors, Steroid)
RN  - 21820-51-9 (Phosphotyrosine)
RN  - EC 2.7.10.1 (ERBB4 protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.10.1 (Receptor, ErbB-4)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Breast Neoplasms/*metabolism/pathology
MH  - ErbB Receptors/*metabolism
MH  - Female
MH  - Frozen Sections
MH  - Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry
MH  - Phosphorylation
MH  - Phosphotyrosine/metabolism
MH  - Prognosis
MH  - Proto-Oncogene Mas
MH  - Receptor Protein-Tyrosine Kinases/*metabolism
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptor, ErbB-4
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Receptors, Steroid/*metabolism
MH  - Retrospective Studies
PMC - PMC1861670
EDAT- 1996/02/01 00:00
MHDA- 1996/02/01 00:01
PMCR- 1996/08/01
CRDT- 1996/02/01 00:00
PHST- 1996/02/01 00:00 [pubmed]
PHST- 1996/02/01 00:01 [medline]
PHST- 1996/02/01 00:00 [entrez]
PHST- 1996/08/01 00:00 [pmc-release]
PST - ppublish
SO  - Am J Pathol. 1996 Feb;148(2):549-58.